Guildford, UK, 7 August 2013: ReNeuron announced on 22 July 2013 the details of a Placing in which it had conditionally raised proceeds of £25.35 million before expenses.
Result of General Meeting
ReNeuron wins £1.5 million UK Government grant for Phase II stroke trial
Guildford, UK, 1 August 2013: ReNeuron is pleased to announce that it has been awarded a £1.5 million grant from the Technology Strategy Board (TSB), an innovation agency of the UK Government, under its Supporting Regenerative Medicines and Cell Therapies Competition.
Rt Hon Danny Alexander MP Visits ReNeuron
Rt Hon Danny Alexander MP Visits ReNeuron
On Tuesday 23rd July 2013, the Chief Secretary to the Treasury, the Rt Hon Danny Alexander MP, visited ReNeuron’s laboratories.
Webcast of 2013 Preliminary Results presentation to analysts
Please click on link below for webcast of 2013 Preliminary Results presentation to analysts.
http://mediaserve.buchanan.uk.com/2013/reneuron220713/registration.asp.
sf.kdnslkjdsnfljk
Unaudited Preliminary Results for the Year Ended 31 March 2013
Guildford, UK, 22 July 2013: ReNeuron is pleased to announce its preliminary results for the year ended 31 March 2013.
ReNeuron announces £33 million financing package. Placing to raise up to £25.35 million, grant package of £7.8 million from Welsh Government and Notice of General Meeting
Guildford, UK, 22 July 2013: ReNeuron is pleased to announce that it has raised a total of £33 million in a financing package that transforms the Company’s prospects and helps position it as a global leader in stem cell development.
Notification of Preliminary Results
Guildford, UK, 1 July 2013: ReNeuron will announce its preliminary results for the year ended 31 March 2013 on Thursday 25 July 2013.
ReNeuron welcomes recommendations in House of Lords Science and Technology Committee report on Regenerative Medicine
Guildford, UK, 1 July 2013: ReNeuron welcomes the recommendations in the House of Lords Science and Technology Committee’s report, Regenerative Medicine, published today.
Media Coverage of Interim data from clinical trial of ReNeuron’s stem cell therapy for stroke
Interim data from clinical trial of ReNeuron’s stem cell therapy for stroke to be presented at leading stroke conference. Longer term data continue to show good safety profile and evidence of sustained reductions in neurological impairment and spasticity
Guildford, UK, 28 May 2013: ReNeuron provides an update on progress with the PISCES clinical trial of its ReN001 stem cell therapy for disabled stroke patients.